Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.
Spero Therapeutics, Inc. (SPRO) Cash Flow from Financial Activities data is not available for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$41.30M |
|
$31.52M |
|
-- |
|
$41.30M |
|
$9.89M |
|
$31.41M |
|
$0.38M |
|
$31.78M |
|
$31.78M |
|
$31.52M |
|
$31.52M |
|
$31.52M |
|
$31.52M |
|
$31.41M |
|
$31.41M |
|
56.02M |
|
59.04M |
|
$0.56 |
|
$0.56 |
|
| Balance Sheet Financials | |
$67.29M |
|
-- |
|
$1.63M |
|
$68.92M |
|
$8.87M |
|
-- |
|
$1.03M |
|
$9.90M |
|
$59.02M |
|
$59.02M |
|
$59.02M |
|
56.41M |
|
| Cash Flow Statement Financials | |
$-12.62M |
|
-- |
|
|
Cash Flow from Financial Activities |
-- |
$52.89M |
|
$40.27M |
|
$-12.62M |
|
$4.33M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.59 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
76.05% |
|
76.05% |
|
-- |
|
76.96% |
|
76.33% |
|
$-12.62M |
|
-- |
|
-- |
|
-- |
|
0.60 |
|
-- |
|
1.63 |
|
55.33 |
|
53.40% |
|
53.40% |
|
45.73% |
|
53.40% |
|
$1.05 |
|
$-0.21 |
|
$-0.21 |
|